92P Neoadjuvant multimodality RX including immunotherapy for highly selective unresectable locally advanced esophageal squamous cell carcinoma (NEXUS): A prospective, single-arm, phase II trial. (December 2022) - Wang, X.; Chen, X.; Kang, X.; Zhang, R.; Qu, D.; Xue, L.; Cheng, G.; Xi, G.; Zhang, T.; Deng, L.; Liu, W.; Bi, N.; et al.